Category: New products
-
University, Startup Develop Low-Power, High-Impact Display
A collaboration between University of Cincinnati’s (UC’s) Novel Devices Laboratory, and startup company Gamma Dynamics LLC, also in Cincinnati, Ohio have created an electrofluidic display that provides a full color, high-impact image at a fraction of the power needed for current color hand-held and tablet devices. Electrofluidic displays use colored liquids to display the various…
-
Safer Catalysts Developed for Power Plant Pollutants
A research team at Lehigh University in Bethlehem, Pennsylvania has developed catalysts that convert the harmful nitrogen oxides emitted from coal- and gas-fired power plants to nitrogen and water vapor. Unlike current methods, the catalysts developed with nanotechnology do not use ammonia or need high temperatures to work. Charles Lyman, professor of materials science and…
-
Stanford Univ. Licenses IVF Technology
Auxogyn Inc., a medical technology company in Menlo Park, California says it acquired an exclusive license from Stanford University to develop products that can help improve the effectiveness of in vitro fertilization (IVF) procedures. Auxogyn specializes in technologies for women’s reproductive health. A new paper describing the technology licensed from Stanford demonstrates that a human…
-
Biotech Company, Universities Produce Artificial Spider Silk
A joint R&D project by University of Notre Dame in South Bend, Indiana, University of Wyoming in Laramie, and Kraig Biocraft Laboratories Inc. in Lansing, Michigan has succeeded in producing transgenic (genetically engineered) silkworms capable of spinning artificial spider silks. Natural spider silks have a number of unusual physical properties, including higher tensile strength and…
-
Process Validated for Purifying Protein-Based Drugs
Scientists at Rensselaer Polytechnic Institute in Troy, New York, are using nuclear magnetic resonance to understand and improve the process of purifying drugs that use proteins, which are notoriously difficult to separate from other potentially deadly impurities. A team led by Steven Cramer, professor of polymer engineering at Rensselaer studied the process of multimodal chromatography…
-
First Wave Energy Device Connected to Power Grid
Ocean Power Technologies (OPT) in Pennington, New Jersey, says it has completed the first-ever grid connection of a wave energy device in the United States at Marine Corps Base Hawaii on Oahu. The grid connection uses OPT’s PowerBuoy systems to produce what the company calls utility-grade, renewable energy that can be delivered compliant with national…
-
Technique Revealed to Curb Farm Ammonia Emissions
A soil scientist and engineer team at the USDA’s Agricultural Research Service (ARS) has found a way for dairy farmers to reduce ammonia emissions from their production facilities: injecting liquid manure into crop fields below the soil surface. A study conducted by soil scientist April Leytem and agricultural engineer David Bjorneberg at the ARS Northwest…
-
Nestlé to Open Health Science Subsidiary and Research Institute
Nestlé, the global food and health products company based in Switzerland, announced today the creation of Nestlé Health Science S.A. and the Nestlé Institute of Health Sciences to expand the company’s industrial presence in nutrition and wellness. Nestlé says the two new organizations — one an operating division and the other an R&D center —…
-
Study: Tactile Signals Can Give Directions to Drivers
A new study finds drivers talking on cell phones and not hearing spoken instructions from a passenger or navigation system, can still get directions from devices mounted on the steering wheel. Nate Medeiros-Ward, a psychology doctoral student at University of Utah in Salt Lake City will present the findings tomorrow at the annual meeting of…
-
Trial Shows Positive Results for Hodgkin Lymphoma Drug
Seattle Genetics Inc., a biotech company in Bothell, Washington, and and Millennium, a developer of cancer drugs in Cambridge, Massachusetts, today released positive top-line results from a trial of their drug brentuximab vedotin. The drug is antibody-drug conjugate that works like an antibody carrying molecules toxic to cancer cells, targeted to CD30, a marker for…